Q4 25 EPS
$5.03
MISS 2.30%
Est. $5.15
Q4 25 Revenue
$3.19B
BEAT +0.48%
Est. $3.17B
vs S&P Since Q4 25
-5.9%
TRAILING MARKET
VRTX +1.7% vs S&P +7.6%
Full Year 2025 Results
FY 25 EPS
$18.40
FY 25 Revenue
$12.00B
Market Reaction
Did VRTX Beat Earnings? Q4 2025 Results
Vertex Pharmaceuticals delivered a standout fourth quarter, posting non-GAAP EPS of $5.03 against a consensus estimate of $4.40, a beat of 14.28%, while revenue of $3.19 billion topped expectations by 4.56% and climbed 15.2% year over year. The headl… Read more Vertex Pharmaceuticals delivered a standout fourth quarter, posting non-GAAP EPS of $5.03 against a consensus estimate of $4.40, a beat of 14.28%, while revenue of $3.19 billion topped expectations by 4.56% and climbed 15.2% year over year. The headline driver was a powerful combination of continued strength in the company's cystic fibrosis franchise, particularly the ongoing U.S. Rollout of ALYFTREK, and a lower effective tax rate that included a one-time benefit from previously deferred tax credits. Beyond the CF core, newer products added meaningful texture to the quarter: CASGEVY generated $54.30 million in revenue with 30 patient infusions, while JOURNAVX contributed $26.70 million following more than 550,000 prescriptions written since its March launch, signaling early commercial diversification taking hold. Looking ahead, Vertex guided FY 2026 revenue of $12.95 billion to $13.10 billion, with non-CF products expected to contribute at least $500 million, a threshold that underscores how meaningfully the company's growth story is broadening beyond its legacy franchise.
Key Takeaways
- • Continued strong CF patient demand including ALYFTREK adoption
- • Higher realized net prices in CF versus prior year
- • Modest benefit from CF channel inventory in Q4
- • Contributions from CASGEVY and JOURNAVX commercial launches
- • Lower effective tax rate due to one-time benefit from recognition of previously deferred tax credits
VRTX YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
VRTX Revenue by Segment
With YoY comparisons, source: SEC Filings
VRTX Revenue by Geography
With YoY comparisons, source: SEC Filings
“2025 marked a year of strong revenue growth, commercial diversification, and pipeline advancement. Our focus in 2026 remains on executing across the CF franchise, bringing CASGEVY to more patients around the globe and continuing to launch JOURNAVX, as we also prepare for the anticipated near-term commercialization of povetacicept in IgAN. With expanding leadership in CF, exciting commercial momentum, and multiple mid- and late-stage programs advancing, Vertex is well positioned to deliver long-term value for patients and shareholders.”
— Reshma Kewalramani, Q4 2025 Earnings Press Release
VRTX Earnings Trends
VRTX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
VRTX EPS Trend
Earnings per share: estimate vs actual
VRTX Revenue Trend
Quarterly revenue: estimate vs actual
VRTX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $4.31 | $4.47 | +3.81% | $2.99B | -0.36% |
| Q4 25 MISS FY | $5.15 | $5.03 | -2.30% | $3.19B | +0.48% |
| FY Full Year | — | $18.40 | — | $12.00B | — |
| Q3 25 BEAT | $4.58 | $4.80 | +4.87% | $3.08B | +0.56% |
| Q2 25 BEAT | $4.25 | $4.52 | +6.33% | $2.96B | +2.00% |
| Q1 25 MISS | $4.29 | $4.06 | -5.44% | $2.77B | -3.17% |